Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/14/2012

CRANBURY, N.J., Nov. 14, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2012. 

Recent Highlights
On July 3, 2012, Palatin closed on a private placement of 3,873,000 shares of its common stock, Series A 2012 warrants to purchase up to 31,988,151 shares of its common stock, and Series B 2012 warrants to purchase up to 35,488,380 shares of its common stock. Aggregate gross proceeds to Palatin were $35,000,000, with net proceeds, after deducting offering expenses, of $34,407,446.

On September 27, 2012, at a special meeting Palatin stockholders voted to increase its authorized common stock from 100,000,000 to 200,000,000 shares, and Palatin filed a certificate of amendment with the Secretary of State of Delaware the same day. This satisfied certain contractual obligations relating to the Series B 2012 warrants in its 2012 private placement, so that interest will not be payable on the value of the Series B 2012 warrants and Palatin will not be required to redeem the Series B 2012 warrants for failure to increase the number of authorized shares.

On November 8, 2012, Palatin reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD). The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or a combination of both disorders, the most common types of FSD, demonstrate that women taking bremelanotide showed clinically meaningful and statistically significant increases
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 20, 2014 One of the ... is an inadequate vascular supply. Nutrient and gas ... tissues is critical for successful regeneration and integration ... mitigate deficiencies in vascularization and promote angiogenesis in ... optimizing scaffold design and architecture, and enhancing scaffolds ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Shimadzu ... chromatography systems, Prominence-i and Nexera-i, adding to the ... Combining excellent functionality, an intuitive operating environment, and ... a more efficient workflow for conventional to ultra-high-speed ... innovative, intuitive and intelligent design so users can ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
(Date:8/19/2014)... 19, 2014 A Geisinger researcher on a ... a Centers for Disease Control and Prevention (CDC) award ... health concern. Joseph Boscarino , Ph.D. ... a team of researchers nominated for the Centers for ... Award for Data Methods and Study Design. ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... Advanced Instruments, Inc., of,Norwood, Massachusetts, announced today ... D & F Control Systems, Inc., of Dublin, ... D & F Control Systems manufactures and ... laboratories around the world. Their,patented preservatives ensure component ...
... Operations Appointed -, CLINTON, N.J., Oct. 2 ... Michael Kennedy as Senior Vice President,Engineering and Operations. ... technology strategy and development., "Michael,s extensive experience ... as we continue to advance our pharmaceutical,pipeline through ...
... the largest non-state-owned producers of ... plasma-based product in China, ... (OTC Bulletin Board: CBPO) ("China Biologic" or the,"Company"), one of ... ("PRC"), today announced that on September 26,2008, the Company has ...
Cached Biology Technology:Advanced Instruments Acquires D & F Control Systems Inc. 2Ikaria Strengthens Executive Leadership Team 2China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 2China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 3China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 4China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 5
(Date:8/19/2014)... have identified a biomarker strongly associated with basal-like ... resistant to many types of chemotherapy. The biomarker, ... for new therapeutics designed to treat this often ... taken from The Cancer Genome Atlas, molecular biologists ... powerful computational and bioinformatics techniques to detect patterns ...
(Date:8/19/2014)... ancestors of today,s crocodiles colonised the seas during warm ... a new Anglo-French study which establishes a link between ... over a period of more than 140 million years. ... from the Universit de Lyon, France and formerly from ... in Nature Communications ., Today, crocodiles are ,cold-blooded, ...
(Date:8/19/2014)... fizzy soda knows that bubbles can throw tiny particles ... industrial applications, Princeton researchers have demonstrated that the bursting ... well. , "It is well known that bursting bubbles ... to discover that when we covered the water with ... the water," said Howard Stone, the Donald R. Dixon ...
Breaking Biology News(10 mins):Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3Evolution of marine crocodilians constrained by ocean temperatures 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... wringing every drop of energy from as many photons ... chemistry, materials science and electronic engineering researchers on a ... but existing techniques are now running up against limits ... Now, researchers from the University of Pennsylvania and Drexel ...
... BURLINGTON, Mass. , Nov. 12, 2013  Decision Resources, ... for pharmaceutical and healthcare issues, finds that while most ... play a critical role in pharmaceutical development of chronic ... outside of oncology is building. The Strategic Insights report ...
... more meat, milk and eggs in their diets. Increased ... livestock production and massive environmental consequences at local, regional ... Treatment and Management, draws from Danish expertise and spotlights ... work and ensure the use of animal manure,s stinking ...
Cached Biology News:Penn and Drexel team demonstrates new paradigm for solar cell construction 2Penn and Drexel team demonstrates new paradigm for solar cell construction 3Penn and Drexel team demonstrates new paradigm for solar cell construction 4Penn and Drexel team demonstrates new paradigm for solar cell construction 5Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing 2New textbook tackles the sustainable recycling of manure 2
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
Mouse monoclonal antibody raised against a partial recombinant KRT4. NCBI Entrez Gene ID = KRT4...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... PrecisION Ion Channel Cell Lines ,High Quality, ... channels are well known for having a ... and consequently have a key function in ... modulate ion channels have been investigated in ...
Biology Products: